Provided by Tiger Fintech (Singapore) Pte. Ltd.

Puma Biotechnology

3.40
+0.04001.19%
Post-market: 3.400.00000.00%18:11 EDT
Volume:395.41K
Turnover:1.33M
Market Cap:168.77M
PE:4.40
High:3.42
Open:3.40
Low:3.34
Close:3.36
Loading ...

Douglas M. Hunt, SVP of Regulatory Affairs, Reports Disposal of Common Shares in Puma Biotechnology Inc

Reuters
·
11 Jul

Alan H. Auerbach, President and CEO, Reports Disposal of Common Shares of Puma Biotechnology Inc

Reuters
·
11 Jul

BRIEF-Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
03 Jul

Puma Biotechnology Updates Bylaws for Compliance

TIPRANKS
·
25 Jun

Director Alessandra Cesano Reports Disposal of Common Shares of Puma Biotechnology Inc

Reuters
·
18 Jun

Puma Biotechnology Inc. Conducted Annual Stockholders Meeting

Reuters
·
14 Jun

Puma Biotechnology Announces New Inducement Awards for Non-Executive Employees Under 2017 Incentive Plan

Reuters
·
05 Jun

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Jun

Puma Biotechnology Terminates Chief Commercial Officer

TIPRANKS
·
09 May

Puma Biotechnology Inc - on May 8 Terminates Chief Commercial Officer Jeff J. Ludwig - SEC Filing

THOMSON REUTERS
·
09 May

Puma Biotechnology Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Puma Biotechnology Q1 Adj. EPS $0.10 Beats $(0.02) Estimate, Sales $46.00M Beat $44.55M Estimate

Benzinga
·
09 May

Puma Biotechnology Reports Q1 2025: NERLYNX Sales Rise to $43.1 Million, Net Income Hits $3.0 Million, EPS at $0.06

Reuters
·
09 May

BRIEF-Puma Biotechnology Q1 Adjusted EPS USD 0.1

Reuters
·
09 May

Puma Biotechnology Inc expected to post a loss of 2 cents a share - Earnings Preview

Reuters
·
07 May

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 May

Er-Kim Announces Exclusive Distribution Agreement With Puma Biotechnology to Commercialize Nerlynx® (Neratinib) for Breast Cancer Patients

THOMSON REUTERS
·
30 Apr

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

GlobeNewswire
·
30 Apr

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Business Wire
·
29 Apr

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Business Wire
·
25 Apr